COPD Therapeutics Market Forecast Size & Forecast 2033

Q: What is the market value in 2023?

The market in 2023 is valued at US$ 12,144.1 million. Read Report

Q: How was the market’s historical performance?

The market rose at a 4.8% CAGR from 2018 to 2022. Read Report

Q: What is the likely CAGR until 2033?

The market will register a 5.1% CAGR until 2033. Read Report

Q: What will be the market value in 2033?

By 2033, the market will reach US$ 20,035.5 million. Read Report

Q: What was Europe’s market share in 2022?

Europe’s market share in 2022 was 29.8%. Read Report

COPD Therapeutics Market Outlook (2023 to 2033)

The global COPD therapeutics market garnered a market value of US$ 12,144.1 million in 2023 and is expected to accumulate a market value of US$ 20,035.5 million by 2033, registering a CAGR of 5.1% over the forecast period.

The growth of the COPD therapeutics market can be attributed to an increase in smoking and genetic disorders. The market for COPD therapeutics registered a CAGR of 4.8% during the historical period.

Report Attribute	Details
Estimated Base Year Value (2022)	US$ 11,668.2 million
Expected Market Value (2023)	US$ 12,144.1 million
Anticipated Forecast Value (2033)	US$ 20,035.5 million
Projected Growth Rate (2023 to 2033)	5.1% CAGR

Surgery is recommended in case of the extreme severity of COPD, including lung volume reduction surgery, lung transplant, and bullectomy, and the adoption of COPD therapeutics rises as COPD is one of the leading causes of death worldwide.

Triple therapy, LABA-ICS, LAMA-ICS, and other combination medications are examples of combination therapy. As using a bronchodilator and a corticosteroid separately is less effective, combination therapy is becoming more popular, positively impacting the market outlook.

Combination therapy is superior to monotherapy for treating the signs and symptoms of chronic obstructive pulmonary disease and enhancing the quality of life. Moreover, the COPD therapeutics market growth is anticipated to rise as a result of a rise in the number of patients who are successfully treated with combination therapy but did not improve after receiving bronchodilators or corticosteroids.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Which Are Some Prominent Drivers of the COPD Therapeutics Market?

Lifestyle change is responsible for increasing the habits like smoking and increase in the number of genetic disorders, which in turn are responsible for raising the number of COPD patients and expanding the COPD therapeutics market size.

Other factors that can boost the revenue from the COPD therapeutics market are rising healthcare expenditures, leading to the adoption of COPD treatments in emerging economies. The demand for COPD therapeutics can also be owed to an increase in the level of awareness which has also led to the early diagnosis of COPD so that people can go for the treatment of the disease.

Additionally, it is projected that new product launches and advances in the global market for Chronic Obstructive Pulmonary therapeutics in respiratory illness therapy will aid in the industry's expansion. Betterment of the healthcare infrastructure in the Asia Pacific and the Middle East, and Africa is also responsible for the revenue growth of the COPD therapeutics market during the forecast period.

What Are the Challenges Faced by the COPD Therapeutics Market?

Factors that can limit the growth of the therapeutic enzymes over the forecast period include the fact that not all patients suffering from COPD are aware of the fact that they are suffering from the disease and therefore do not go for the treatment of the disease.

Also, sometimes people get to know about their disease when only medication and therapies, and surgery can’t cure the disease becomes mandatory. This factor can also lead to sluggish growth in the revenue from the COPD therapeutics market.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How Is the Prevalence of COPD Escalating Demand for COPD Therapeutics in North America?

Region	North America
Market Share % (2022)	36.2%

According to National Heart, Lung, and Blood Institute, more than 15 million people are affected by COPD. This has increased the dependency on COPD therapeutics to access early treatment for the same. In addition, the strong presence of key players in the region is accelerating the growth of the COPD therapeutics market.

Moreover, developing health infrastructure is fuelling the growth of the COPD therapeutics market. Thus, due to the aforementioned reasons, North America is expected to possess more than 36.2% market share for COPD therapeutics in 2023.

How are Government Initiatives Augmenting Demand for COPD Therapeutics in Europe?

Region	Europe
Market Share % (2022)	29.8%

According to Asthma Lung UK+, more than 1.3 million people suffer from COPD. This has led the country's government to design initiatives to create awareness regarding COPD. In addition, the increasing geriatric population in the country is contributing to the growth of the COPD market.

Furthermore, the growing inclination towards early treatment positively influences the market's growth. Thus, due to the reasons mentioned above, Europe is expected to hold a more than 29.8% COPD therapeutics market share in 2023.

What Are A Few Key Start-Ups in The COPD Therapeutics Market?

Key start-up players in the COPD therapeutics market are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat, and ReAlta Life Sciences.

ReAlta Life Sciences, a key start-up in the COPD therapeutics market develops engineered peptides to harness the power of the immune system. In addition, the drug also works for COVID-19 patients.
Spirosure, a US-based start-up, raised US$ 32 million in funding, aimed at making the lives of people with respiratory disorders like COPD, asthma, cystic fibrosis, and pulmonary hypertension better by developing breath-based diagnostic and monitoring tools.

How Strong Is the Competition in The COPD Therapeutics Market?

The COPD market is consolidated, with only a few significant firms present, and the primary strategies used by the top companies are product portfolio expansion and mergers and acquisitions.

One of the major recent developments in the COPD therapeutics market is when AstraZeneca’s Bevespi Aerospherehas received approval in China as a maintenance treatment to relieve symptoms in patients suffering from COPD.

Key players

Pfizer Inc.
Adamis Laboratories Inc.
GlaxoSmithKline plc.
AstraZeneca
Merk & Co.
Novartis AG
Mylan N.V.
Teva Pharmaceutical Industries

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 12,144.1 million
Market Value in 2033	US$ 20,035.5 million
Growth Rate	CAGR of 5.1% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Component End User Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa
Key Countries Profiled	The United States Canada Brazil Mexico Germany The United Kingdom France Spain Italy Nordics BENELUX Australia & New Zealand China Japan South Korea India ASEAN GCC South Africa
Key Companies Profiled	Pfizer Inc. Adamis Laboratories Inc. GlaxoSmithKline plc AstraZeneca Merk & Co Novartis AG Mylan N.V. Teva Pharmaceutical Industries
Customization	Available Upon Request

Key Segments Profiled in the COPD Therapeutics Industry Survey

By Component:

COPD Therapeutics Drug Class
Bronchodilators
Steroids
Phosphodiesterase-4 inhibitors
Theophylline
Antibiotics
COPD Therapeutics Delivery Systems
Oral
Inhalation

By End User:

Hospitals
Private Clinics
Outpatient Departments

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Frequently Asked Questions

What is the market value in 2023?

The market in 2023 is valued at US$ 12,144.1 million.

How was the market’s historical performance?

The market rose at a 4.8% CAGR from 2018 to 2022.

What is the likely CAGR until 2033?

The market will register a 5.1% CAGR until 2033.

What will be the market value in 2033?

By 2033, the market will reach US$ 20,035.5 million.

What was Europe’s market share in 2022?

Europe’s market share in 2022 was 29.8%.

Table of Content

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Component
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Component, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component, 2023 to 2033
5.3.1. Drug Class
5.3.2. Bronchodilators
5.3.3. Steroids
5.3.4. Phosphodiesterase-4 inhibitors
5.3.5. Theophylline
5.3.6. Antibiotics
5.3.7. Delivery Systems
5.3.8. Oral
5.3.9. Inhalation
5.4. Y-o-Y Growth Trend Analysis By Component, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Component, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Private Clinics
6.3.3. Outpatient Departments
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Component
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Component
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Component
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Component
9.3.3. By End User
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Component
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Component
10.3.3. By End User
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Component
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Component
11.3.3. By End User
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Component
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Component
12.3.3. By End User
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Component
13.2.3. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Component
13.3.3. By End User
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Component
14.2.3. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Component
14.3.3. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Component
15.1.2.2. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Component
15.2.2.2. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Component
15.3.2.2. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Component
15.4.2.2. By End User
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Component
15.5.2.2. By End User
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Component
15.6.2.2. By End User
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Component
15.7.2.2. By End User
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Component
15.8.2.2. By End User
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Component
15.9.2.2. By End User
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Component
15.10.2.2. By End User
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Component
15.11.2.2. By End User
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Component
15.12.2.2. By End User
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Component
15.13.2.2. By End User
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Component
15.14.2.2. By End User
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Component
15.15.2.2. By End User
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Component
15.16.2.2. By End User
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Component
15.17.2.2. By End User
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Component
15.18.2.2. By End User
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Component
15.19.2.2. By End User
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Component
15.20.2.2. By End User
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Component
15.21.2.2. By End User
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Component
15.22.2.2. By End User
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Component
15.23.2.2. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Component
16.3.3. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Pfizer Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Adamis Laboratories Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. GlaxoSmithKline plc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. AstraZeneca Plc
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Merk & Co.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Novartis AG
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Mylan N.V.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Teva Pharmaceutical Industries
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Abbott Laboratories
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Almirall
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Astellas Pharma
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Boehringer Ingelheim Pharmaceuticals, Inc.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Orion Corporation
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Sunovion Pharmaceuticals, Inc.
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology

COPD Therapeutics Market

A Detailed Analysis of COPD Therapeutics Market by COPD Therapeutics Drug Class, Bronchodilators, Steroids, Phosphodiesterase-4 inhibitors, Theophylline, Antibiotics, COPD Therapeutics Delivery Systems, Oral, Inhalation